NOTE
magnetismm-3
- Design: Phase 2 trial, single-center, open-label
- Number of patients: 123
- Patient characteristics: Patients with relapsed or refractory multiple myeloma without prior BCMA-directed therapy
- Agent: Elranatamab, subcutaneous once weekly after two step-up priming doses, with some patients switching to biweekly dosing
- Treatment line: Patients with relapsed or refractory multiple myeloma
- Trial Acronym: MagnetisMM-3
- Compare efficacy:
| Parameter | Result |
|---|---|
| Confirmed ORR | 61.0% |
| Complete response | 35.0% |
| Median duration of response | Not reached |
| Progression-free survival rate at 15 months | 50.9% |
| Overall survival rate at 15 months | 56.7% |
- Highlight of toxicity: Common adverse events included infections, cytokine release syndrome, anemia, and neutropenia. Grade 3-4 adverse events decreased with biweekly dosing.
- One line summary: Elranatamab showed promising efficacy in patients with relapsed/refractory multiple myeloma, with manageable toxicity profile and potential benefit from switching to biweekly dosing.